Seymour LW, Fisher KD. British Journal of Cancer. 2016;114:357–61
Reviews
Recent Posts
- PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers
- PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases
- PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration
- Priya Mande, PsiOxus COO, listed in the Top 25 Women Leaders in Biotechnology for 2020
- PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer
